{"id":354,"date":"2026-04-29T03:04:45","date_gmt":"2026-04-29T03:04:45","guid":{"rendered":"https:\/\/isbm-technology.com\/?p=354"},"modified":"2026-04-29T03:04:45","modified_gmt":"2026-04-29T03:04:45","slug":"isbm-cream-ointment-bottles-pet-packaging-for-topical-pharmaceutical-products","status":"publish","type":"post","link":"https:\/\/isbm-technology.com\/fa\/application\/isbm-cream-ointment-bottles-pet-packaging-for-topical-pharmaceutical-products\/","title":{"rendered":"ISBM Cream & Ointment Bottles: PET Packaging for Topical Pharmaceutical Products"},"content":{"rendered":"

<\/p>\n

\n

<\/p>\n

\n
<\/div>\n
<\/div>\n
<\/div>\n

Australia Ever-Power Injection Stretch Blow Moulding Machine Co., Ltd \u2014 Condell Park NSW 2200<\/p>\n

A technically detailed guide for topical pharmaceutical manufacturers, dermatology product developers, and healthcare packaging engineers on how injection stretch blow molding<\/strong> delivers the leak prevention, dispensing precision, chemical compatibility, and contamination control that cream, ointment, and lotion pharmaceutical container systems require in Australia’s TGA-regulated healthcare market.<\/p>\n

ISBM Bottle Manufacturing<\/span>
\nInjection Stretch Blow Molding<\/span>
\nPET Blow Molding<\/span>
\nCustom PET Bottle Solutions<\/span><\/div>\n<\/header>\n

<\/p>\n

\n

Topical Pharmaceutical Packaging: Where Dermatology Formulation Meets Precision Container Engineering<\/h2>\n

Topical pharmaceutical products \u2014 prescription and over-the-counter creams, ointments, gels, lotions, and emulsions \u2014 represent one of the most commercially significant pharmaceutical dosage forms in Australian healthcare. Dermatological conditions including eczema, psoriasis, acne, fungal infections, and inflammatory skin disorders affect a substantial proportion of the Australian population, and the topical products used to treat them require packaging that protects formulation stability over the product’s shelf life, prevents microbial contamination during repeated use, and facilitates accurate dose application to the treatment area. The interaction between the topical formulation chemistry and the container material is often the most technically challenging aspect of packaging development for this dosage form, because creams and ointments contain complex mixtures of oils, emulsifiers, active pharmaceutical ingredients, and preservative systems that each have distinct packaging interaction profiles.<\/p>\n

The injection stretch blow molding machine<\/a> provides topical pharmaceutical packaging operations with the dimensional precision, chemical compatibility breadth, and production consistency that cream, ointment, and lotion containers require \u2014 while maintaining the GMP-compliant production documentation that TGA pharmaceutical registration demands.<\/p>\n

Australia Ever-Power Injection Stretch Blow Moulding Machine Co., Ltd, operating from Condell Park NSW 2200, supports topical pharmaceutical manufacturers and dermatology product developers with ISBM machine technology and pharmaceutical application engineering calibrated for the specific requirements of topical product container development and production in the Australian market.<\/p>\n<\/section>\n

<\/p>\n

\"Cream
Topical pharmaceutical packaging \u2014 cream, ointment, lotion, and gel containers from ISBM production meeting TGA dermatological product registration requirements for chemical compatibility, dispensing precision, and contamination prevention.<\/figcaption><\/figure>\n

<\/p>\n

\n

Topical Formulation Chemistry and PET Container Compatibility<\/h2>\n

Cream and ointment pharmaceutical formulations present a wide range of chemical compatibility challenges for container materials. Unlike aqueous pharmaceutical solutions, topical formulations contain significant concentrations of hydrophobic phase components \u2014 vegetable oils, mineral oils, petroleum jelly, silicones, waxes \u2014 along with emulsifiers, co-solvents, and active pharmaceutical ingredients that may include corticosteroids, retinoids, antifungal agents, antibiotics, and keratolytic agents. Each of these components has its own partition behaviour between the formulation and the container wall, and their combined effect on container performance must be assessed through formal stability studies rather than component-by-component compatibility data alone.<\/p>\n

Oil-in-Water Emulsions (Creams and Lotions)<\/h3>\n

Standard pharmaceutical creams and lotions in the oil-in-water (O\/W) emulsion form \u2014 with an aqueous continuous phase containing 15\u201340% dispersed oil phase \u2014 are generally compatible with PET containers at normal storage temperatures (15\u201330\u00b0C). The continuous aqueous phase limits direct oil-polymer contact to the droplet interfaces, and PET’s hydrophilic surface provides a lower-energy interface for emulsion droplets than more hydrophobic polymers like HDPE or PP. The primary compatibility concern for O\/W creams in PET is emulsion stability \u2014 any change in the microstructure of the emulsion caused by container interactions (specifically, any surfactant adsorption onto the PET surface that depletes emulsifier from the formulation) could cause phase separation, creaming, or coalescence during storage. Formal emulsion stability testing in the production container at 25\u00b0C\/60% RH and 40\u00b0C\/75% RH (ICH conditions) confirms whether this is a real issue for the specific formulation.<\/p>\n

Water-in-Oil Emulsions and Pure Ointments<\/h3>\n

Water-in-oil (W\/O) emulsions (rich creams, cold creams) and pure ointment bases (petroleum jelly, soft paraffin, polyethylene glycol bases) have continuous oil or wax phases that are in direct prolonged contact with the container wall. For these formulations, the oil-polymer compatibility must be assessed specifically \u2014 petroleum jelly and mineral oil have extensive compatibility data with PET at ambient temperatures, but synthetic ester oils and some vegetable oils at elevated temperature may show minor PET surface interaction (very slight surface whitening or haze increase at the contact interface) that must be characterised in the stability study. For prescription-strength pharmaceutical ointments where even minor container interaction could affect product performance or regulatory compliance, the stability study is a non-negotiable development step before committing to PET as the commercial container material.<\/p>\n

Active Pharmaceutical Ingredient Interactions<\/h3>\n

Topical APIs with known packaging interaction risks include: corticosteroids (can adsorb onto polymer surfaces, potentially depleting active from the formulation over the product’s shelf life); retinoids (photosensitive and susceptible to oxidation \u2014 UV-protective container or secondary packaging is required); antifungal azoles (can interact with some polymer additives); and organic sunscreen agents (partition strongly into hydrocarbon polymers). For each API class with known interaction potential, the stability study should specifically monitor API assay (confirming no depletion from adsorption) and degradation product profile (confirming no polymer-induced degradation pathways) at both ICH stability conditions. ISBM’s ability to produce tinted or UV-protective PET containers is directly relevant for photosensitive topical APIs like retinoids and vitamin D derivatives.<\/p>\n<\/section>\n

<\/p>\n

\n

Dispensing and Dose Control for Topical Pharmaceutical Containers<\/h2>\n

Accurate dose application is a clinical efficacy requirement for topical pharmaceuticals \u2014 particularly for potent corticosteroids and targeted antifungal treatments where over-application risks systemic side effects (for corticosteroids with significant percutaneous absorption) and under-application risks therapeutic failure. The container’s dispensing system must enable the patient to apply the intended dose \u2014 typically a defined area coverage (expressed in “fingertip units” for patient guidance) \u2014 without inadvertent over-dispensing from a bottle that delivers too large a stream, or under-dispensing from a nozzle that clogs or drips after dispensing.<\/p>\n

\n
\n
\ud83d\udc8a<\/div>\n

Pump Dispenser Systems<\/h4>\n

Metered pump dispensers on cream and lotion bottles provide the most accurate dose control \u2014 each pump stroke delivers a calibrated volume (typically 0.5\u20131.5g per stroke for standard cream formulations). The ISBM bottle’s 28\/410 or 24\/410 pump neck finish must meet the pump supplier’s dimensional tolerances (\u00b10.08mm thread diameter, \u00b10.06mm roundness) for reliable pump engagement and the sealing performance that prevents cream leakage between pump actuations.<\/p>\n<\/div>\n

\n
\ud83d\udd04<\/div>\n

Flip-Top Dispensing Caps<\/h4>\n

Disc-top or flip-top closures provide simple dispensing for creams and lotions with appropriate viscosity for gravity or gentle squeeze dispensing. ISBM’s injection neck provides the transfer bead height (\u00b10.10mm) that flip-top closures require for positive tamper-evident engagement and reliable resealing \u2014 preventing cream drying at the orifice between uses.<\/p>\n<\/div>\n

\n
\ud83d\udcd0<\/div>\n

Squeeze Tube Compatibility<\/h4>\n

For ointments and high-viscosity creams requiring squeeze tube dispensing from a flexible PET or PETG container, ISBM’s wall flexibility engineering (targeting 6\u201315N squeeze force at the body midpoint) must be calibrated to the specific formulation’s viscosity \u2014 thick petroleum-based ointments require more squeeze force than standard aqueous creams to initiate flow through the orifice.<\/p>\n<\/div>\n

\n
\ud83d\udeab<\/div>\n

Anti-Drip Nozzle Design<\/h4>\n

Cream formulations with high water content (standard O\/W lotions) can drip after dispensing if the closure orifice geometry is not correctly matched to the formulation’s surface tension and viscosity. Injection-formed nozzle geometry with a defined orifice entry radius eliminates post-dispensing drool \u2014 a common patient complaint that leads to product waste and poor patient adherence to topical treatment regimens.<\/p>\n<\/div>\n<\/div>\n<\/section>\n

<\/p>\n

\"Cream
Topical pharmaceutical dispensing systems \u2014 pump, flip-top, and squeeze formats for cream, lotion, and ointment packaging from ISBM production with injection-precision neck finishes enabling reliable metered dose dispensing and anti-drip orifice performance.<\/figcaption><\/figure>\n

<\/p>\n

\n

Contamination Prevention for Multi-Use Topical Pharmaceutical Containers<\/h2>\n

Most topical pharmaceutical products are packaged in multi-use containers opened and reclosed many times over a treatment course of days to months. Each opening and application event introduces the risk of microbial contamination from the patient’s hands, the treatment site (which may itself be infected in conditions like infected eczema or tinea), and the ambient environment. The preservative system in the formulation is the primary defence against in-use contamination \u2014 the container design is the secondary defence that limits contamination entry between doses.<\/p>\n

ISBM container design contributes to contamination prevention through: the closure’s tip shield that covers the orifice between uses (keeping the highest-risk zone \u2014 where the cream contacts both the patient and the container \u2014 sealed between applications); the induction foil seal that provides a hermetic microbial barrier from manufacture to first opening (removing all uncertainty about the container’s contamination history at the point of first use); and the container body’s smooth interior that does not have crevices or dead zones where contaminated formulation can accumulate and re-contaminate fresh product during dispensing.<\/p>\n

The Ph.Eur. Antimicrobial Preservative Effectiveness Test (Test B criteria for topical preparations) must be conducted on the commercial formulation in the production container with the commercial closure at the beginning and end of the simulated in-use period \u2014 confirming that the preservative system maintains adequate antimicrobial efficacy throughout the product’s labelled in-use shelf life (typically 3\u20136 months after opening) in the production container at the storage conditions recommended on the label. Contact sales@isbm-technology.com<\/a> for preservation efficacy protocol guidance for your specific topical product and ISBM container combination.<\/p>\n<\/section>\n

<\/p>\n

\n

Packaging Formats Across the Topical Pharmaceutical Range<\/h2>\n

The topical pharmaceutical market encompasses a wide variety of product formats, each with distinct container requirements that ISBM addresses through format-specific preform and tooling design. Understanding these format-specific requirements is the basis for specifying the correct ISBM container for each topical product type.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n
Product Type<\/th>\nVolume Range<\/th>\nKey Container Req.<\/th>\nClosure System<\/th>\nISBM Material<\/th>\n<\/tr>\n<\/thead>\n
Prescription corticosteroid cream<\/td>\n15g \u2013 100g<\/td>\nAPI adsorption study, induction seal<\/td>\nScrew cap + induction foil<\/td>\nPET or PETG<\/td>\n<\/tr>\n
OTC antifungal cream<\/td>\n15g \u2013 50g<\/td>\nAnti-drip nozzle, easy opening<\/td>\nFlip-top or screw cap<\/td>\nPET<\/td>\n<\/tr>\n
Body lotion \/ moisturiser (OTC)<\/td>\n100ml \u2013 500ml<\/td>\nMetered dose pump, visual appeal<\/td>\nLotion pump 24\/410<\/td>\nPET or PETG clear<\/td>\n<\/tr>\n
Pharmaceutical gel (topical analgesic)<\/td>\n30g \u2013 150g<\/td>\nSqueeze force calibration, gel viscosity dispensing<\/td>\nDisc-top or flip-top<\/td>\nPETG (flexibility)<\/td>\n<\/tr>\n
Retinoid cream \/ Vitamin D ointment<\/td>\n15g \u2013 60g<\/td>\nUV protection (amber), API stability study<\/td>\nScrew cap + induction foil<\/td>\nAmber PET<\/td>\n<\/tr>\n
Sunscreen SPF product<\/td>\n75ml \u2013 250ml<\/td>\nUV-filter API sorption study, pump or flip-top<\/td>\nPump or disc-top<\/td>\nPET or PETG<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/section>\n

<\/p>\n

\"Pharmaceutical
Topical pharmaceutical container format range from ISBM \u2014 corticosteroid cream bottles, antifungal gel tubes, body lotion pumps, and sunscreen dispensers produced with format-specific dispensing geometry, material compatibility, and TGA registration documentation support.<\/figcaption><\/figure>\n

<\/p>\n

\n

TGA Registration for Topical Pharmaceutical PET Containers<\/h2>\n

Topical pharmaceutical products registered on the ARTG as prescription (Schedule 4) or over-the-counter (Schedule 2\/3) medicines require container-closure system specification in the CTD registration dossier. The specific documentation requirements for topical product containers differ in several ways from those for oral and parenteral containers, reflecting the distinct route of administration, the formulation complexity of topical dosage forms, and the predominance of multi-use containers that require in-use contamination assessment.<\/p>\n

\n
\n
01<\/div>\n
\n

Container-Closure System Specification<\/h4>\n

Dimensional drawing with tolerances; material specification (PET resin grade, masterbatch description); closure description with induction seal specification if used. For amber containers: UV transmission data confirming light protection equivalent to amber glass at the product’s photosensitivity wavelength range.<\/p>\n<\/div>\n<\/div>\n

\n
02<\/div>\n
\n

Extractables and Leachables (Topical Route)<\/h4>\n

E&L assessment using dermal contact conditions (extended contact with the topical formulation at use temperature) with TTC values appropriate for dermal absorption routes. Corticosteroid and other potent API assay confirmation at stability time points confirming no depletion from adsorption to container wall.<\/p>\n<\/div>\n<\/div>\n

\n
03<\/div>\n
\n

Stability Programme (ICH Q1A)<\/h4>\n

25\u00b0C\/60% RH long-term and 40\u00b0C\/75% RH accelerated stability data confirming physical appearance, API assay, preservative efficacy (for preserved formulations), viscosity\/rheology (for gels), and pH stability in the production container over the proposed shelf life.<\/p>\n<\/div>\n<\/div>\n

\n
04<\/div>\n
\n

Preservative Efficacy (Multi-Use Products)<\/h4>\n

Ph.Eur. 5.1.3 Test B criteria for topical preparations \u2014 antimicrobial challenge testing with the full range of specified organisms at the beginning of and during the in-use period. Must be conducted in the production container with commercial closure to confirm that preservative activity is maintained throughout the product’s labelled in-use shelf life.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

<\/p>\n

\n

Dermatology Market Dynamics and ISBM Production Economics<\/h2>\n

The Australian dermatological pharmaceutical market spans three commercial tiers: prescription brands, generic prescription products, and OTC dermatology. Each tier has distinct packaging economics and quality requirements that affect the ISBM production configuration appropriate for the specific product.<\/p>\n

Prescription dermatology brand products \u2014 corticosteroids, retinoids, calcineurin inhibitors \u2014 are produced in smaller volumes (50,000\u2013500,000 units per year per SKU) at higher unit values, where the packaging development investment in custom bottle design and full pharmaceutical registration documentation is justified by the product’s price point and commercial longevity. ISBM single-cavity tooling is appropriate for these volumes, with the development programme including the complete TGA dossier CCS documentation. Generic prescription dermatology products require the same documentation standards as brands (identical TGA registration pathway) but are produced at higher volumes (200,000\u20132M units per year) where multi-cavity ISBM tooling delivers the production economics that generic pricing requires.<\/p>\n

OTC dermatology products \u2014 antifungal creams, antiseptic preparations, moisturisers with TGA-listed claims \u2014 are produced at higher volumes again (500,000\u201310M units per year) with more flexible packaging development pathways and stronger commercial drivers for packaging differentiation and brand identity. For Australian OTC dermatology brands, ISBM’s custom bottle design capability and the commercial differentiation that proprietary packaging creates is a direct revenue driver \u2014 products in distinctively designed, premium-appearance ISBM containers command meaningful retail price premiums over commodity alternatives in Australia’s competitive pharmacy retail environment.<\/p>\n<\/section>\n

<\/p>\n

\"Dermatology
Topical pharmaceutical ISBM production across prescription, generic, and OTC dermatology tiers \u2014 custom bottle design for brand differentiation, multi-cavity production economics for generic volumes, and full TGA CCS documentation for registration compliance.<\/figcaption><\/figure>\n

<\/p>\n

\n

Sustainable Packaging for Topical Pharmaceutical Products<\/h2>\n

Topical pharmaceutical packaging sustainability occupies a pragmatic space \u2014 the regulatory pathway for container changes requires TGA variation management as described for all pharmaceutical container changes, but the dermal-route pharmacology of topical products and the lower sensitivity to extractables (versus parenteral routes) means the E&L reassessment for rPET or lightweighting changes is less extensive than for injectable applications. For OTC topical products where the TGA approval pathway is more flexible than for prescription registration, sustainability improvements are more readily implemented without full variation processes.<\/p>\n

Lightweighting within the validated container specification \u2014 reducing preform weight without changing the commercial container’s dimensions or performance specification \u2014 is the lowest-regulatory-risk sustainability intervention for topical pharmaceutical ISBM containers. A 10\u201315% preform weight reduction achieved through ISBM process optimisation that does not change the container’s dimensional specification typically falls within the manufacturing variation clause of a registered pharmaceutical dossier in Australia, without requiring a TGA variation. The material saving, embodied carbon reduction, and environmental on-pack claim enabled by a lightweighting programme are commercially meaningful for OTC dermatology brands with active sustainability communications to their consumer base.<\/p>\n

For registered prescription topical products, any container change including lightweighting must be assessed against the registered container specification and, if the change falls outside the approved specification ranges, managed through the appropriate TGA variation pathway. Contact sales@isbm-technology.com<\/a> for regulatory change control guidance for topical pharmaceutical container sustainability programmes under TGA requirements.<\/p>\n<\/section>\n

<\/p>\n

\n

Production Quality Management for Topical Pharmaceutical ISBM Operations<\/h2>\n

Topical pharmaceutical ISBM operations producing containers for TGA-registered products must maintain a GMP-compliant quality management system covering incoming material release, in-process controls, finished container inspection, and batch record documentation. The specific quality attributes critical for topical pharmaceutical containers are: neck finish dimensions (for closure compatibility and pump\/flip-top engagement); body wall thickness distribution (for squeeze force and emulsion stability performance); induction seal surface dimensions (for hermetic seal integrity); and colour\/tint consistency for amber containers (for photosensitivity protection compliance).<\/p>\n

For pump-dispensed topical pharmaceutical containers, an additional in-process quality check \u2014 pump engagement force and pump stroke volume testing on a sample from each production cavity using the commercial pump component \u2014 confirms that the production neck finish dimensions produce the pump engagement performance validated in the container-closure system qualification. Any cavity producing pumps with engagement force outside the acceptance range triggers a dimensional investigation of that cavity’s neck insert tooling dimensions.<\/p>\n

The batch record for topical pharmaceutical ISBM production must include: resin CoC and release documentation, process parameter log from the ISBM machine data logging system, in-process dimensional inspection results, pump engagement testing results (if applicable), finished container visual inspection records, and QA sign-off. These records are retained per TGA GMP requirements and are the documentation basis for any product recall investigation that may implicate the container in a product quality event.<\/p>\n<\/section>\n

<\/p>\n

\n

Ever-Power’s Topical Pharmaceutical ISBM Development Support<\/h2>\n

Australia Ever-Power provides topical pharmaceutical manufacturers and dermatology product developers with a complete ISBM container development support programme \u2014 from initial container design through TGA registration documentation. The development programme includes: dispensing system selection and qualification protocol design (pump stroke volume validation, flip-top engagement and anti-drip testing); formulation compatibility study design for the specific topical formulation chemistry; container-closure system GMP production documentation; and the IQ\/OQ\/PQ validation framework for the ISBM production process.<\/p>\n

For Australian dermatology brands currently sourcing topical containers from offshore suppliers, Ever-Power’s pre-investment analysis demonstrates the commercial advantage of local ISBM production: elimination of 8\u201314 week import lead times (critically important for OTC seasonal demand and promotional cycle responsiveness), custom bottle design capability that offshore commodity sourcing cannot support, and the regulatory supply chain security of knowing that the container manufacturer operates under Australian pharmaceutical GMP oversight.<\/p>\n

Visit isbm-technology.com\/contact-us<\/a> to begin your topical pharmaceutical container ISBM development conversation with Australia Ever-Power’s pharmaceutical packaging specialist team.<\/p>\n<\/section>\n

<\/p>\n

\"ISBM
Australia Ever-Power’s Condell Park NSW facility \u2014 ISBM machines for topical pharmaceutical container production with GMP documentation capability, dispensing qualification support, and TGA registration dossier development assistance for Australian dermatology pharmaceutical manufacturers.<\/figcaption><\/figure>\n
Request a Topical Packaging Technical Assessment \u2192<\/a><\/div>\n

<\/p>\n

\n

Recommended Machine<\/p>\n

HGYS150-V4-B \u2014 Four-Station ISBM for Topical Pharmaceutical Production<\/h2>\n
\n
\n

For topical pharmaceutical container production spanning prescription cream bottles, OTC dermatology dispensers, and body lotion pump formats across 15g\u2013500ml volumes, the HGYS150-V4-B four-station one-step ISBM machine<\/a><\/strong> provides the production flexibility and pharmaceutical compliance capability that the dermatology packaging sector requires. The four-station rotary architecture delivers consistent cavity-to-cavity neck finish precision \u2014 critical for pump and flip-top closure compatibility across the full production run. The machine processes PET and PETG with equal precision, accommodating the material flexibility required by topical formulation diversity: standard PET for O\/W cream and lotion applications, PETG for flexible gel tube formats, and amber masterbatch PET for photosensitive topical APIs. PLC process data logging with audit-trail recipe management generates the pharmaceutical GMP batch records required for TGA-registered topical product packaging. Rapid mould changeover (90\u2013180 minutes for full changeover) supports multi-SKU dermatology product ranges from a single machine platform, reducing capital overhead for topical pharmaceutical operations producing across multiple product lines.<\/p>\n

View HGYS150-V4-B Specifications \u2192<\/a><\/p>\n<\/div>\n

\"HGYS150-V4-B<\/div>\n<\/div>\n<\/section>\n

<\/p>\n

\"Complete
Topical pharmaceutical container range from ISBM \u2014 prescription corticosteroid cream bottles, antifungal dispensers, amber retinoid packaging, body lotion pump systems, and gel tubes meeting TGA registration CCS requirements for chemical compatibility, preservative efficacy, and dispensing precision.<\/figcaption><\/figure>\n

<\/p>\n

\n

Frequently Asked Questions: ISBM for Cream & Ointment Pharmaceutical Bottles<\/h2>\n
\n
\n1. Can PET ISBM containers hold petroleum jelly-based ointments without degradation?+<\/span><\/summary>\n
Petroleum jelly (white soft paraffin) and mineral oil-based ointments are compatible with PET at ambient storage temperatures (15\u201330\u00b0C) based on the chemical similarity between the saturated hydrocarbon ointment base and PET’s low affinity for alkane solvents. The primary compatibility concern at higher temperatures (above 40\u00b0C) is dimensional stability \u2014 petroleum jelly has a softening range of 38\u201360\u00b0C depending on the specific grade, and above its softening range it becomes a low-viscosity liquid that exerts hydrostatic pressure on the container wall. PET at these temperatures (approaching but still below its Tg of 75\u201380\u00b0C) remains rigid but may show very minor dimensional creep under sustained liquid pressure at temperatures above 50\u00b0C over extended periods. For ointments stored in standard ambient conditions (below 30\u00b0C) throughout their shelf life, formal stability testing at 40\u00b0C\/75%RH for 6 months typically confirms compatibility without issue. Ever-Power recommends a short compatibility evaluation at accelerated conditions for any petroleum-based ointment in PET ISBM containers before committing to commercial production \u2014 the study is straightforward and takes 6\u20138 weeks, providing definitive data rather than relying on general compatibility statements.<\/div>\n<\/details>\n
\n2. How is the pump stroke volume validated for metered-dose topical pharmaceutical dispensers?+<\/span><\/summary>\n
Pump stroke volume validation for metered-dose topical dispensers involves measuring the mass of product dispensed per pump actuation at defined conditions \u2014 standard temperature (+20\u00b0C), defined actuation speed (mimicking a typical patient actuation), and defined bottle orientation (vertical). A minimum of 30 independent pump actuation measurements per cavity (each measurement comprising 10 consecutive strokes, with the mean mass per stroke calculated for each set) provides the statistical dataset for calculating the mean stroke volume, standard deviation, and the coefficient of variation (CV) \u2014 which should be \u22645% for a well-performing pump dispenser system. The pump stroke volume is a combined property of the pump mechanism design (supplied by the closure manufacturer) and the container neck finish and body geometry \u2014 the container must provide the specific neck finish engagement dimensions that the pump manufacturer specifies, and the container body wall must not deform under the pump’s downstroke force in a way that affects the internal pressure during dispensing. Validation must be conducted on the specific pump and container combination from all production cavities \u2014 pump stroke volume validated on one cavity is not representative of the multi-cavity production population. Ever-Power provides metered pump validation protocol templates as part of the topical pharmaceutical ISBM development support service.<\/div>\n<\/details>\n
\n3. What amber tint specification is needed for photosensitive topical products in ISBM containers?+<\/span><\/summary>\n
The light protection specification for topical pharmaceutical amber containers depends on the photosensitivity wavelength range of the active pharmaceutical ingredient. Retinoids (tretinoin, adapalene, retinol) are primarily sensitive in the UV-A and UV-B range (280\u2013400nm); Vitamin D analogues (calcipotriol) are sensitive across the visible range extending into UV-A; certain antibiotic topicals are sensitive at specific UV-B wavelengths. The pharmacopoeial reference for amber glass equivalence \u2014 light transmission \u226410% at wavelengths below 450nm through the container wall at production nominal thickness \u2014 provides a practical starting specification for most topical photosensitive applications. The amber masterbatch loading required to achieve this specification in the ISBM container at the production nominal wall thickness is determined during container development by measuring spectrophotometric transmission at multiple wavelengths through body panel specimens at the production wall thickness, and adjusting the masterbatch loading until the specification is met across the full wavelength range of concern. For products where photostability study data (ICH Q1B) identifies sensitivity outside the 280\u2013450nm range, the transmission specification must be extended to cover the identified sensitive wavelengths. The amber masterbatch colourant system must be included in the container’s E&L extractables study \u2014 confirming no chromophore-derived extractables exceed the dermal-route TTC at the product contact conditions.<\/div>\n<\/details>\n
\n4. Can the same ISBM machine produce different topical pharmaceutical formats (cream, lotion, gel) in the same week?+<\/span><\/summary>\n
Yes \u2014 a single ISBM machine with configurable tooling serves multiple topical pharmaceutical container formats through scheduled changeovers. A typical week’s production schedule for a topical pharmaceutical operation might include: 2 production shifts on a 50g corticosteroid cream bottle, a 3-hour changeover to a 150ml lotion pump format, 1.5 production shifts on the lotion format, a 2-hour colour changeover within the same tooling, and 1 production shift on the amber version of the cream bottle. The pharmaceutical GMP requirement for product changeover is more stringent than commercial packaging \u2014 each product changeover must include a documented line clearance procedure that confirms no previous product materials (containers, labels, in-process samples) remain in the production area before the new product commences, and the first containers produced after changeover must pass the in-process dimensional inspection and colour verification before the production lot is opened. The ISBM machine’s electronic recipe management system allows the validated process parameters for each container format and colour to be stored and recalled without manual re-entry \u2014 preventing the parameter transcription errors that manual recipe setup creates and providing the audit trail documentation that pharmaceutical changeover procedures require. With well-managed production scheduling and clean changeover procedures, a single ISBM machine can serve a topical pharmaceutical range of 10\u201320 SKUs from one capital platform.<\/div>\n<\/details>\n
\n5. How does ISBM handle the TGA registration variation process when changing from a previous container to a PET ISBM container?+<\/span><\/summary>\n
Changing from an existing registered container to a PET ISBM container for a TGA-registered topical pharmaceutical product requires a post-registration variation application to the TGA. The variation category depends on the magnitude of the change: changing from one PET container to a different PET ISBM container with the same material classification (both pharmacopoeial-grade PET for the same application) is typically a Level 1 variation supported by a comparability statement and brief stability bridging data. Changing from a non-PET container (HDPE, glass, PE tube) to PET ISBM is typically a Level 2 variation requiring a full comparative CCS package including extractables, stability comparability, and preservative efficacy data in the new container. The TGA variation review timeline for Level 1 and Level 2 variations is 30 and 180 calendar days respectively (approximate \u2014 varies with submission quality and TGA workload). For topical pharmaceutical manufacturers planning a container transition, the variation preparation and submission process should be initiated at least 6 months before the desired commercial transition date to accommodate the variation review period. Ever-Power provides container specification documentation and technical data package support for TGA variation submissions \u2014 contact sales@isbm-technology.com<\/strong> to discuss the variation support package for your specific topical product and container transition programme.<\/div>\n<\/details>\n<\/div>\n<\/section>\n<\/div>","protected":false},"excerpt":{"rendered":"

Australia Ever-Power Injection Stretch Blow Moulding Machine Co., Ltd \u2014 Condell Park NSW 2200 A technically detailed guide for topical pharmaceutical manufacturers, dermatology product developers, and healthcare packaging engineers on how injection stretch blow molding delivers the leak prevention, dispensing precision, chemical compatibility, and contamination control that cream, ointment, and lotion pharmaceutical container systems require […]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-354","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/isbm-technology.com\/fa\/wp-json\/wp\/v2\/posts\/354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/isbm-technology.com\/fa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/isbm-technology.com\/fa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/isbm-technology.com\/fa\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/isbm-technology.com\/fa\/wp-json\/wp\/v2\/comments?post=354"}],"version-history":[{"count":1,"href":"https:\/\/isbm-technology.com\/fa\/wp-json\/wp\/v2\/posts\/354\/revisions"}],"predecessor-version":[{"id":357,"href":"https:\/\/isbm-technology.com\/fa\/wp-json\/wp\/v2\/posts\/354\/revisions\/357"}],"wp:attachment":[{"href":"https:\/\/isbm-technology.com\/fa\/wp-json\/wp\/v2\/media?parent=354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/isbm-technology.com\/fa\/wp-json\/wp\/v2\/categories?post=354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/isbm-technology.com\/fa\/wp-json\/wp\/v2\/tags?post=354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}